Property | Value |
?:abstract
|
-
BACKGROUND: A new stain of corona virus COVID-19 got worldwide attention and has affected almost whole of the world population. Currently there is no specific vaccine or drug against COVID-19. Xu et al. (2020) built a homolog model of SARS-CoV-2 Mpro based on SARS-CoV Mpro which is considered as target to inhibit the replication of CoV. OBJECTIVE: The aim of current study is to find potential inhibitors of COVID-19 Mpro using docking analysis. METHODS: Autodockvina was used to carry out Protein-Ligand docking. COVID-19 main protease Mpro was docked with catechin and its different synthetic derivatives. Nelfinavir is an antiretroviral drug belongs to protease inhibitors was taken as standard. RESULTS: According to the result obtained it was found that Compound (4) and Compound (1) have more affinity than nelfinavir. CONCLUSION: Compounds have a great potential to become COVID-19 main protease Mpro inhibitor. Nevertheless for their medicinal use further investigation is necessary.
|
is
?:annotates
of
|
|
?:creator
|
|
?:journal
|
-
Combinatorial_chemistry_&_high_throughput_screening_(Online)
|
?:license
|
|
?:publication_isRelatedTo_Disease
|
|
?:source
|
|
?:title
|
-
Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking studies unveils an opportunity against CORONA
|
?:type
|
|
?:who_covidence_id
|
|
?:year
|
|